Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children with Growth Hormone Deficiency.
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2018
Price : $35 *
At a glance
- Drugs Somavaratan (Primary)
- Indications Growth disorders; Somatotropin deficiency
- Focus Registrational; Therapeutic Use
- Acronyms VELOCITY
- Sponsors Versartis
- 13 Oct 2017 This study has been completed in Belgium as per European Clinical Trials Database.
- 11 Oct 2017 Status changed from active, no longer recruiting to completed.
- 21 Sep 2017 Results presented in a Versartis media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History